Skip to main content
. 2017 Oct;137(10):2197–2207. doi: 10.1016/j.jid.2017.05.030

Figure 2.

Figure 2

Expression of MHC class II is specific to melanocytes and OIS. (a) Western blot of BRAFV600E expression in melanocytes, keratinocytes, and fibroblasts transduced with a vector encoding BRAFV600E (B) or control vector (V). (b) HLA-DRA and HLA-DRB transcript levels detected by quantitative real-time reverse transcriptase–PCR analysis, in melanocytes (mel), fibroblasts (fib), or keratinocytes (ker). ND indicates no signal detected. (c) Staining for SA ß-gal activity in melanocytes in exponential growth phase (PD 26) or at replicative senescence (PD 43). Scale bar = 50 μm. (d) Quantification of SA ß-gal– and BrdU-positive melanocytes. (e) HLA-DRA and HLA-DRB transcript levels in melanocytes detected by quantitative real-time reverse transcriptase–PCR. (f) Western blots of HRASG12V, NRASQ61K, BRAFV600E, MEKQ56P, and myrAKT expression and knockdown of PTEN. (g) Quantification of SA ß-gal staining (left) and EdU incorporation (right) of melanocytes transduced as indicated. (h) HLA-DRA and HLA-DRB transcript levels detected by quantitative real-time reverse transcriptase–PCR of melanocytes transduced as indicated. (i) Western blot showing expression of BRAFV600E and SV40 T antigen. (j) Quantification of SA ß-gal staining and EdU incorporation of melanocytes transduced with BRAFV600E and SV40 T-antigen. (k) All graphs show means ± standard deviation, n = 4. MHC, major histocompatibility complex; SA ß-gal, senescence-associated β-galactosidase; SA-Bgal, senescence-associated β-galactosidase.